Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Palatin Technologies (PTN)

Palatin Technologies (PTN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 29,531
  • Shares Outstanding, K 16,137
  • Annual Sales, $ 4,850 K
  • Annual Income, $ -27,540 K
  • 60-Month Beta 0.86
  • Price/Sales 6.35
  • Price/Cash Flow N/A
  • Price/Book 20.44
Trade PTN with:

Options Overview Details

View History
  • Implied Volatility 109.53% ( -35.49%)
  • Historical Volatility 80.80%
  • IV Percentile 34%
  • IV Rank 16.05%
  • IV High 587.95% on 05/09/24
  • IV Low 18.05% on 10/16/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 147
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 4,105
  • Open Int (30-Day) 4,255

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.65
  • Number of Estimates 1
  • High Estimate -0.65
  • Low Estimate -0.65
  • Prior Year -0.91
  • Growth Rate Est. (year over year) +28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7900 +5.59%
on 05/30/24
2.4800 -23.79%
on 05/13/24
+0.0300 (+1.61%)
since 04/30/24
3-Month
1.4600 +29.45%
on 03/20/24
2.8800 -34.38%
on 04/08/24
-0.1200 (-5.97%)
since 02/29/24
52-Week
1.4300 +32.17%
on 09/28/23
5.6500 -66.55%
on 01/29/24
-0.5500 (-22.54%)
since 05/26/23

Most Recent Stories

More News
Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders

EQNX::TICKER_START (NYSE:PTN),(NASDAQ:RYTM),(NASDAQ:VKTX),(NASDAQ:GPCR),(NYSE:NVO) EQNX::TICKER_END

PTN : 1.8600 (+1.64%)
RYTM : 36.66 (+3.53%)
VKTX : 62.99 (-1.29%)
GPCR : 35.49 (-2.02%)
NVO : 133.29 (+0.46%)
Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders

/PRNewswire/ -- The Melanocortin Receptor 4 (MC4R) is a protein-coupled receptor primarily expressed in the central nervous system, playing a pivotal role in...

PTN : 1.8600 (+1.64%)
RYTM : 36.66 (+3.53%)
VKTX : 62.99 (-1.29%)
GPCR : 35.49 (-2.02%)
NVO : 133.29 (+0.46%)
Palatin Announces Preliminary Quarter Ended September 30, 2023 Vyleesi® Product Revenue Results

/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...

PTN : 1.8600 (+1.64%)
Palatin Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients

/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...

PTN : 1.8600 (+1.64%)
Palatin Receives Notice of Non-Compliance from NYSE American

/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...

PTN : 1.8600 (+1.64%)
Palatin Reports Fourth Quarter and Fiscal Year Ended 2023 Financial Results and Provides Corporate Update

Enrollment in Phase 3 PL9643 MELODY-1 Study in Dry Eye Disease (DED) is Complete with 570 Patients Enrolled Topline Data Expected Late 4Q Calendar Year 2023...

PTN : 1.8600 (+1.64%)
Palatin to Report Fourth Quarter and Fiscal Year End 2023 Results; Teleconference and Webcast to be held on September 28, 2023

/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2023 operating results on Thursday,...

PTN : 1.8600 (+1.64%)
Palatin to Present at the H.C. Wainwright 25th Annual Global Investment Conference

/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...

PTN : 1.8600 (+1.64%)
Palatin Completes Enrollment in Phase 3 MELODY-1 Study of PL9643 For the Treatment of Patients with Dry Eye Disease

/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...

PTN : 1.8600 (+1.64%)
PLN Signs Cooperation with TANESCO to Develop Electricity Ecosystem in Tanzania

PLN Signs Cooperation with TANESCO to Develop Electricity Ecosystem in Tanzania

PTN : 1.8600 (+1.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Palatin Technologies, Inc is a development-stage medical technology companyinvolved in developing and commercializing products and technologies fordiagnostic imaging, cancer therapy and ethical drug development These developments are based on its proprietary monoclonal antibody radiolabeling and enabling...

See More

Key Turning Points

3rd Resistance Point 1.9518
2nd Resistance Point 1.9275
1st Resistance Point 1.8787
Last Price 1.8600
1st Support Level 1.8056
2nd Support Level 1.7813
3rd Support Level 1.7325

See More

52-Week High 5.6500
Fibonacci 61.8% 4.0380
Fibonacci 50% 3.5400
Fibonacci 38.2% 3.0420
Last Price 1.8600
52-Week Low 1.4300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar